Gaska Jenna M, Ding Qiang, Ploss Alexander
Lewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
School of Medicine, Tsinghua University, Beijing, China.
Methods Mol Biol. 2019;1911:481-503. doi: 10.1007/978-1-4939-8976-8_33.
In spite of the immense progress in hepatitis C virus (HCV) research, efforts to prevent infection, such as generating a vaccine, have not yet been successful. The high price tag associated with current treatment options for chronic infection and the spike in new infections concurrent with growing opioid abuse are strong motivators for developing effective immunization and understanding neutralizing antibodies' role in preventing infection. Humanized mice-both human liver chimeras as well as genetically humanized models-are important platforms for testing both possible vaccine candidates as well as antibody-based therapies. This chapter details the variety of ways humanized mouse technology can be employed in pursuit of learning how HCV infection can be prevented.
尽管丙型肝炎病毒(HCV)研究取得了巨大进展,但诸如研发疫苗等预防感染的努力尚未成功。慢性感染当前治疗方案的高昂价格以及与阿片类药物滥用增加同时出现的新感染激增,是推动开发有效免疫方法和了解中和抗体在预防感染中作用的强大动力。人源化小鼠——包括人肝脏嵌合体以及基因人源化模型——是测试潜在疫苗候选物和基于抗体疗法的重要平台。本章详细介绍了可利用人源化小鼠技术来探索如何预防HCV感染的各种方法。